Related Experiment Video
Updated: Jun 17, 2026
05:33
Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting
Published on: August 4, 2023
Gabapentin use in hyperemesis gravidarum: a pilot study
Thomas Guttuso1, Luther K Robinson, Kofi S Amankwah
1Department of Neurology, University at Buffalo, 3435 Main Street, 311 BRB, Buffalo, NY 14214, USA. tguttuso@buffalo.edu <tguttuso@buffalo.edu>
Early Human Development
|December 18, 2009
Summary
Gabapentin therapy significantly reduced nausea and vomiting in hyperemesis gravidarum (HG) patients. However, two congenital defects were observed in seven infants exposed to gabapentin during pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Maternal-Fetal Medicine
Background:
- Hyperemesis gravidarum (HG) is a severe condition characterized by nausea and vomiting during pregnancy.
- Current treatments for HG have limitations and may not be fully effective.
- Investigating novel therapeutic agents for HG is crucial.
Purpose of the Study:
- To evaluate the efficacy of gabapentin in treating hyperemesis gravidarum.
- To assess the impact of gabapentin on nausea and emesis severity in HG patients.
Main Methods:
- A study involving 7 subjects diagnosed with hyperemesis gravidarum.
- Gabapentin therapy was administered to the subjects.
- Nausea and emesis were measured from baseline to Days 12-14.
Main Results:
- Gabapentin therapy was associated with significant mean reductions in nausea (80%) and emesis (94%) from baseline to Days 12-14.
- Two cases of congenital defects were reported among the 7 infants exposed to gabapentin.
Conclusions:
- Gabapentin demonstrates potential efficacy in managing symptoms of hyperemesis gravidarum.
- Further research is warranted to confirm efficacy and thoroughly assess the safety profile of gabapentin in pregnancy, particularly regarding congenital defects.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...